良性前列腺增生生物学标志物的研究进展  

Advances of Biomarkers for Benign Prostatic Hyperplasia

作　　者：王嘉俊 李欣然 李一荣[1] 范俊丽[1] WANG Jiajun;LI Xinran;LI Yirong;FAN Junli(Department of Laboratory Medicine,Zhongnan Hospital of Wuhan University,Wuhan 430071,China)

机构地区：[1]武汉大学中南医院检验科,湖北武汉430071

出　　处：《标记免疫分析与临床》2023年第5期881-886,共6页Labeled Immunoassays and Clinical Medicine

基　　金：国家重点研发计划-老年前列腺增生的综合防治研究与精准风险评估和个体化防治措施应用示范(编号:2021YFC2009302)。

摘　　要：良性前列腺增生是引起中老年男性排尿困难的常见疾病,严重影响患者生活质量,我国近年来发病率逐年增加。良性前列腺增生的早期诊断可提高患者长期的生活质量,并减少不必要的活检,而这有赖于其生物标志物的开发和临床应用。本文综述了关于良性前列腺增生的生物标志物的研究进展,包括了前列腺分泌蛋白、激素、炎症性指标、尿液标志物、基因组学生物标志物几类。Benign prostatic hyperplasia is a common male-specific disease that affects urination in aged male population,which compromises patients’quality of life.The incidence rates have been increased yearly in China.The early diagnosis of BPH could improve patients’long-term quality of life,and reduce unnecessary biopsy,which rely on new biomarkers development and related clinical application.This article reviews the progress of research on biomarkers of BPH,including several categories of prostatic secretory proteins,hormones,inflammatory indicators,urinary markers,and genomic biomarkers.

关 键 词：良性前列腺增生 早期诊断 生物学标志物 前列腺特异性抗原 性激素 急性时相蛋白 

分 类 号：R697.32[医药卫生—泌尿科学]